Flow cytometry, cellular DNA content, and prognosis in human malignancy.

Area of Science:

• Oncology
• Biotechnology
• Medical Diagnostics

Background:

• Flow cytometry is increasingly used to analyze cellular DNA content in human malignancies.
• Understanding the link between DNA content abnormalities and prognosis is crucial for cancer management.

Purpose of the Study:

• To review the prognostic relevance of DNA content flow cytometry across various human malignancies.
• To assess the current database supporting the clinical application of DNA content analysis for patient stratification.

Main Methods:

• Analysis of cellular DNA content using flow cytometry.
• Examination of archival material for DNA content and proliferative characteristics.
• Review of existing data on DNA content abnormalities and patient outcomes for different cancer types.

Main Results:

• Abnormal stemline DNA content can distinguish high- and low-risk patient groups in early breast, bladder, non-small-cell lung, colorectal, ovarian, and cervical carcinomas.
• Prognostic relevance of DNA content flow cytometry is established in several hematologic and pediatric malignancies.
• Tumor cell cycle analysis shows potential prognostic importance, though interpretation remains less certain.

Conclusions:

• Flow cytometry DNA analysis is a valuable tool for stratifying patients based on risk for various cancers.
• Generalizations for clinical decision-making are not advised; prognostic significance must be evaluated per tumor type.
• The existing database for DNA content analysis varies by malignancy, necessitating careful consideration for individual patient assessment.